Prevention of decompensation in cirrhosis: a new youth for β blockers

Affiliations

¹ AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, F-94800, France.
² AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, F-94800, France; INSERM, Unité 1193, Université Paris-Sud, Paris-Saclay, Villejuif, F-94800, France; DHU Hepatinov, Villejuif, F-94800, France. Electronic address: didier.samuel@aphp.fr.

Comment

Sharon Levy et al. Lancet. 2019.

. 2019 Apr 20;393(10181):1571-1572.

doi: 10.1016/S0140-6736(19)30736-6. Epub 2019 Mar 22.

¹ AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, F-94800, France.
² AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, F-94800, France; INSERM, Unité 1193, Université Paris-Sud, Paris-Saclay, Villejuif, F-94800, France; DHU Hepatinov, Villejuif, F-94800, France. Electronic address: didier.samuel@aphp.fr.

No abstract available

Comment on

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J. Villanueva C, et al. Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22. Lancet. 2019. PMID: 30910320 Clinical Trial.